COO Stock Analysis — CooperCompanies
Sector: Healthcare
AI Verdict
CooperCompanies trades at 13.6x next year's earnings with explosive growth expected, so if their moat in specialty healthcare products holds, this is cheap for the growth on offer.
Competitive Moat
CooperCompanies dominates in specialty contact lenses and women's health devices, with regulatory approvals and long-term practitioner relationships creating high switching costs. Their scale in manufacturing and distribution makes it hard for new entrants to match their breadth or reliability.
Summary
A huge jump in forecast earnings (347.1% forward EPS growth) has slashed the forward P/E to 13.6x, putting this healthcare name on deep value watch.
Where It Stands
Shares are flat over the past year (-3.19%), the RSI is at 65.4 (elevated, pullback risk), and the forward P/E of 13.6x is well below the healthcare sector median of 22x.
Key Metrics
- RSI: 65.4 — Near Overbought
- Trailing P/E: 60.7x
- Forward P/E: 13.6x
- PEG Ratio: 0.17
- Earnings Growth: +3.5%
- Revenue Growth: +0.1%
- Market Cap: $14.0B
- Dividend Yield: 0.00%
- 1-Year Return: -3.19%
- 52-Week High: $89.83
- 52-Week Low: $58.89
Analyst Consensus
13 Buy · 10 Hold · 1 Sell (24 analysts)
Bull Case
With earnings expected to surge 347.1% next year, the stock trades at just 13.6x forward earnings—a steep discount for this kind of growth.
Bear Case
The RSI at 65.4 signals elevated risk of a pullback, and if the forward P/E reverts even partway to the trailing 60.7x, holders could see a sharp valuation reset.
Catalyst to Watch
Watch for quarterly earnings—if the company delivers on the 347.1% EPS growth forecast, the low forward P/E could quickly rerate upward.